MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/dmso.s350518

Медицинская библиотека · Diabetes, metabolic syndrome and obesity : targets and therapy · 2022

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.

Teragawa Hiroki, Morimoto Takeshi, Fujii Yuichi, Ueda Tomohiro, Sakuma Mio, Shimabukuro Michio, Arasaki Osamu, Node Koichi, Nomiyama Takashi, Ueda Shinichiro

СтатьяПеревод в очереди

Аннотация

PURPOSE: The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.

PATIENTS AND

METHODS

We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, and blood pressure (BP).

RESULTS

No significant differences were found in baseline eGFR and UACR between the two groups. The eGFR levels were significantly decreased in both groups; however, the UACR level was unchanged in the ANA group but elevated in the SITA group, although the difference did not reach significance between the two groups. The difference in eGFR was affected by the differences in HbA1c level and BP, and the difference in the UACR was affected by the differences in LDL-C level and BP, which were reduced only in the ANA group.

CONCLUSION

These findings imply that the effects of DPP-4 inhibitors on renal function, especially on UACR, may be different between the types of DPP-4 inhibitors.

Для цитирования: Teragawa Hiroki, Morimoto Takeshi, Fujii Yuichi, Ueda Tomohiro, Sakuma Mio, Shimabukuro Michio, Arasaki Osamu, Node Koichi, Nomiyama Takashi, Ueda Shinichiro. Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.. Diabetes, metabolic syndrome and obesity : targets and therapy. 2022. DOI: 10.2147/dmso.s350518.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.